Products, systems, and methods for classifying human colorectal cancer into a consensus molecular subtype (CMS) and for assessing risk of recurrence based on CMS scores and based on risk scores derived from abbreviated gene expression profiles, for determining suitable treatment protocols for human colorectal cancer patients based on the determined CMS classification and based on the determined risk of recurrence, and for administering the suitable treatment protocols.

The present invention relates to a detecting method for colorectal cancer and advanced adenoma group, comprising measuring the relative expression level of MKi67, KRT19, EpCAM, TYMS, PPARG, MCAM, ANKHD1-EIF4EBP3, SNAI2, MMP23B, FOXA2, NPTN, GPR15, TERT, VIM, and ERBB2 genes or proteins encoded by the genes in sample, wherein if the MKi67, KRT19 and EpCAM genes are expressed higher than other genes, it is judged as a normal group, if the TYMS, PPARG, MCAM, and ANKHD1-EIF4EBP3 genes are expressed higher than other genes, it is judged as a colorectal cancer group, if the SNAI2, MMP23B, and FOXA2 genes are expressed higher than other genes, it is judged as an advanced adenoma group or colorectal cancer group, if the NPTN, GPR15, TERT, VIM and ERBB2 genes are expressed higher than other genes, it is judged as an advanced adenoma group.

Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

The invention disclosed herein generally relates to genotyping one or more single nucleotide polymorphisms (SNPs) to stratify cancer risk and/or prognosis.

Provided herein is technology for colorectal neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of colorectal neoplasia in 1) individuals at, older or younger than 50 years of age, or 2) individuals having Lynch Syndrome.

Disclosed are methods and systems for the detection of variants of the SARS-CoV-2 virus that cause COVID-19. For example, disclosed are methods for identifying and/or tracking variants of SARS-CoV-2 comprising: (a) identifying a sample from a subject as positive for SARS-CoV-2 nucleic acid and/or antibodies to SARS-CoV-2; (b) generating a sample-specific SARS-CoV-2 nucleic acid from the sample; (c) performing nucleic acid sequencing on the sample-specific SARS-CoV-2 nucleic acid; and(d) determining whether the nucleic acid sequence comprises a SARS-CoV-2 variant sequence. Also disclosed are systems for performing any portion of the disclosed methods and computer-program products tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to perform any of the steps of the disclosed methods or run any portion of the disclosed systems.

The present invention relates to methods for the classification and stratification of cells within tumours. In one aspect, the invention provides methods for classifying cancer cells into intrinsic cancer subtypes, as well as for diagnosing, prognosing and evaluating a response to therapy for patients afflicted with cancer.

Provided herein are compounds, methods, and compositions for use in determining the cellular origin of circulating cell-free DNA.

The present disclosure relates to a neural ectodermal lineage cellular structure, and compositions and methods related thereto. In some embodiments, the disclosure provides a geometrically isolated neural ectodermal lineage cellular structure (neuruloid) including spatially segregated neuroepithelial cells, sensory placodes, neural crest cells, and epidermal cells having radial organization around a lumen within the neuroepithelial cells. The disclosure also provides methods directed to forming the neural ectodermal lineage cellular structure. The disclosure also provides methods and platforms directed to the neural ectodermal lineage cellular structure.

The present disclosure is related to methods of treating autoimmune disorders in a subject comprising administering immunoglobulin-like transcript 7 (ILT7) binding proteins to a subject having elevated type I interferon gene signature (IFNGS). The present disclosure also relates to methods of reducing pDCs in tissues comprising administering an ILT7-binding protein to a subject in need thereof.